Guidance, NICE advice and quality standards in development | Guidance

Showing 171 to 180 of 389

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]	Technology appraisal guidance	TBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]	Technology appraisal guidance	21 May 2026
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Technology appraisal guidance	TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]	Technology appraisal guidance	TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance	TBC
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]	Technology appraisal guidance	TBC